NCT04432324View on ClinicalTrials.gov

Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 2, 2020

Primary Completion Date

March 3, 2021

Study Completion Date

March 3, 2021

Conditions
COVID-19
Interventions
BIOLOGICAL

Intravenous Immune Globulin

IVIG Intravenous infusion

DRUG

Standard Medical Treatment

SMT

Trial Locations (10)

25198

Hospital Arnau de Vilanova, Lleida

28007

Hospital General Universitario Gregorio Marañón, Madrid

28040

Hospital Clinico San Carlos, Madrid

28702

Hospital Universitario Infanta Sofía, San Sebastián de los Reyes

28905

Hospital Universitario de Getafe, Getafe

08916

Hospital Germans Trias i Pujol, Badalona

08003

Hospital Del Mar, Barcelona

08035

Hospital Universitari Vall d'Hebron, Barcelona

08907

Hospital Universitari de Bellvitge, Barcelona

CP 08041

Hospital de la Santa Creu i Sant Pau, Barcelona

All Listed Sponsors
lead

Instituto Grifols, S.A.

INDUSTRY

NCT04432324 - Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19) | Biotech Hunter | Biotech Hunter